Biovex

BioVex (a subsidiary of Amgen) based in Woburn, MA, USA and Abingdon, UK develops biologics for solid tumours and prophylactic vaccines for infectious diseases.

The Company’s lead program, an oncolytic vaccine, is completing Phase III testing for metastatic melanoma (study fully enrolled). Amgen acquired BioVex in March 2011 for up to $1bn ($425m upfront).